The FDA on March 30, 2017 granted regular approval to TAGRISSO®, for the treatment of patients with metastatic Epidermal Growth Factor Receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR Tyrosine Kinase Inhibitor (TKI) therapy. TAGRISSO® is marketed by AstraZeneca Pharmaceuticals, LP.
Other Pages – Bottom Ad
Advertisement
Subscribe
